CLDN4 and pancreatic neoplasm: By targeting exposed CLDN4, and thus strongly accumulating in pancreatic cancer tissue, D@C-LPs suppressed orthotopic pancreatic cancer growth as well as xenograft pancreatic cancer while causing minimal toxicity to off-target normal tissues.